Richard G. Harris, MD, presented “The Effect of COVID-19 on Large Urology Groups: The LUGPA Perspective” for the Grand Rounds in Urology audience in March, 2020.
How to cite: Harris, Richard G. “The Effect of COVID-19 on Large Urology Groups: The LUGPA Perspective” March, 2020. Accessed Jul 2024. https://grandroundsinurology.com/the-effect-of-covid-19-on-large-urology-groups-the-lugpa-perspective/
The Effect of COVID-19 on Large Urology Groups: The LUGPA Perspective – Summary:
Richard G. Harris, MD, President of LUGPA and UroPartners, discusses the changes being implemented at large urology group practices as a result of the COVID-19 pandemic. He notes how surgery and radiation centers are only treating patients with strong suspicion of high-risk disease, and how patients undergoing current radiation treatment protocols are maintaining continuation of care, with added safety protocols built in. These safety protocols include: hypervigilance for patient and staff safety, including mandatory masks and gloves for all staff; mandatory temperature readings before patients are allowed in the clinic; and evaluating patients prior to clinic admission for possible symptoms of COVID-19. Lastly, Dr. Harris discusses the use of telemedicine in the clinic, and how he hopes regulations that make it easier to see patients remotely will stay in place once the pandemic is behind us.
For other urology-focused information on the COVID-19 pandemic, visit our resource page.
ABOUT THE AUTHOR
Richard Harris, MD, is a board-certified urologist with expertise in the treatment of advanced prostate cancer and health policy. He obtained his BA cum laude from Washington University in St. Louis, Missouri. He then completed a year of graduate work in biological science at the University of Illinois in Chicago, followed by medical school at the Chicago Medical School at Rosalind Franklin University. He completed residency training in general surgery and urology at Loyola University Medical Center in Chicago. Dr. Harris has been involved in clinical drug development and research on over 70 drug trials and has also been on the advisory board for several pharmaceutical companies. Currently, he sits on the Board of Directors of LUGPA and is LUGPA’s President. He is a founding member, CEO, and President of UroPartners, LLC, the largest group of urologists in the Midwest.
Dr. Harris is an Assistant Clinical Professor of Urology at the Loyola University Medical Center. His area of interest is urology and his specialty is advanced prostate cancer. Dr. Harris is also interested in BPH, sexual dysfunction, and kidney stone disease. Dr. Harris is one of the few urologists skilled in cryotherapy for prostate cancer.
